SCHEMBL1730609

SCHEMBL1730609

CO[Si](OC)(OC)C(Cc1ccccc1)[Si](OC)(OC)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.50
SLC6A2 P23975 2/20 0.50
SIGMAR1 Q99720 2/20 0.50
MAOA P21397 1/20 0.50
SLC6A4 P31645 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP2A6 P11509 1/20 0.50
ADORA2A P29274 1/20 0.50
ADORA1 P30542 1/20 0.50
EPHX1 P07099 1/20 0.48
CYP2D6 P10635 1/20 0.47
LAP3 P28838 1/20 0.44
SLC18A2 Q05940 1/20 0.42
ANPEP P15144 1/20 0.42
ALPI P09923 1/20 0.41
PKM P14618 1/20 0.41
PTGS1 P23219 1/20 0.41
XIAP P98170 1/20 0.41
SLC7A5 Q01650 1/20 0.41
TRPA1 O75762 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21271564 0.90 EPHX1 (0.43) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL21271557 0.88 SIGMAR1 (0.39) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL2488884 0.83 SLC6A2 (0.52) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL3210839 0.81 SIGMAR1 (0.43) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL10696904 0.81 SIGMAR1 (0.48) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL27769938 0.80 TAAR1 (0.39) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL1968084 0.79 TAAR1 (0.42) TAAR1SLC6A2SIGMAR1MAOASLC6A4
Ammonia Solution, Strong SCHEMBL28922168 0.79 SIGMAR1 (0.47) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL1765955 0.79 TRPA1 (0.47) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL2181964 0.79 TAAR1 (0.47) TAAR1SLC6A2SIGMAR1MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2118008-A2 ZEOLITE MATERIALS AND SYNTHESIS METHOD THEREOF Katholieke Universiteit Leuven (BE) 2009-11-18 EP claimed
WO-2008095264-A2 ZEOLITE MATERIALS AND SYNTHESIS METHOD THEREOF KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2008-08-14 WO claimed
WO-2005100426-A1 A NANOPARTICLE OF CORE-SHELL TYPE, A METHOD FOR PREPARING THE SAME, A METHOD FOR PREPARING A LOW DIELECTRIC INSULATION FILM BY USING THE SAME, AND A LOW DIELECTRIC INSULATION FILM PREPARED THEREFROM POSTECH FOUNDATION (KR) 2005-10-27 WO claimed
EP-3028299-B1 METHODS AND STRUCTURES FOR PROCESSING SEMICONDUCTOR DEVICES MICRON TECHNOLOGY INC (US) 2021-11-03 EP disclosed
US-11078340-B2 Coated fibers, methods of making, and composite materials reinforced with coated fibers KETTERING UNIVERSITY (US) 2021-08-03 US disclosed
US-20160355646-A1 COATED FIBERS, METHODS OF MAKING, AND COMPOSITE MATERIALS REINFORCED WITH COATED FIBERS KETTERING UNIVERSITY 2016-12-08 US disclosed
US-9449940-B2 Methods and structures for processing semiconductor devices using polymeric materials and adhesives MICRON TECHNOLOGY, INC. (US) 2016-09-20 US disclosed
US-9284456-B2 Superficially porous metal oxide particles, methods for making them, and separation devices using them AGILENT TECHNOLOGIES, INC. (US) 2016-03-15 US disclosed
US-9136244-B2 Semiconductor package having a metal member and a resin mold, which are bonded to a silane coupling agent and an intermediate layer of an oxide film HITACHI, LTD. (JP) 2015-09-15 US disclosed
US-20150206813-A1 METHODS AND STRUCTURES FOR PROCESSING SEMICONDUCTOR DEVICES MICRON TECHNOLOGY, INC. (US) 2015-07-23 US disclosed
US-20150097301-A1 METHODS AND STRUCTURES FOR PROCESSING SEMICONDUCTOR DEVICES MICRON SEMICONDUCTOR PRODUCTS, INC. 2015-04-09 US disclosed
US-20120205010-A1 CORROSION CONTROL METHOD OF METAL HITACHI, LTD. 2012-08-16 US disclosed
EP-1075544-B1 CHEMICALLY MODIFIED NUCLEIC ACIDS AND METHODS FOR COUPLING NUCLEIC ACIDS TO SOLID SUPPORT BAYLOR COLLEGE MEDICINE (US) 2011-11-30 EP disclosed
US-20060275787-A1 Compositions and methods for array-based genomic nucleic acid analysis of biological molecules BRADLEY ALLAN 2006-12-07 US disclosed
US-6979728-B2 Articles of manufacture and methods for array based analysis of biological molecules BAYLOR COLLEGE OF MEDICINE (US) 2005-12-27 US disclosed
WO-2005100426-A1 A NANOPARTICLE OF CORE-SHELL TYPE, A METHOD FOR PREPARING THE SAME, A METHOD FOR PREPARING A LOW DIELECTRIC INSULATION FILM BY USING THE SAME, AND A LOW DIELECTRIC INSULATION FILM PREPARED THEREFROM POSTECH FOUNDATION (KR) 2005-10-27 WO disclosed
US-20050064494-A1 Chemically modified biological molecules and methods for coupling biological molecules to solid support BAYLOR COLLEGE OF MEDICINE (US) 2005-03-24 US disclosed
US-6858713-B1 Chemically modified biological molecules and methods for coupling biological molecules to solid support BAYLOR COLLEGE OF MEDICINE (US) 2005-02-22 US disclosed
US-20020006623-A1 Compositions and methods for array-based genomic nucleic acid analysis of biological molecules NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-01-17 US disclosed
US-6048695-A Chemically modified nucleic acids and methods for coupling nucleic acids to solid support BAYLOR COLLEGE OF MEDICINE (US) 2000-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060275787-A1 Compositions and methods for array-based genomic nucleic acid analysis of biological molecules DNMT3A, DNMT3B, BCR TAAR1 1354/4885SLC6A2 4059/4885SIGMAR1 2185/4885
US-20020006623-A1 Compositions and methods for array-based genomic nucleic acid analysis of biological molecules XRN2, XPA, XRCC6 TAAR1 2336/4885SLC6A2 4091/4885SIGMAR1 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.